-
- Jennifer Tran
- Department of Internal Medicine, Cleveland Clinic, Cleveland, OH
-
- Moshe C. Ornstein
- Department of Hematology & Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
抄録
<jats:p> Renal cell carcinomas vary considerably in their tumor biology and disease course, which is reflected in the range of treatment paradigms in localized and metastatic renal cell carcinoma (mRCC). Active surveillance remains an important component of all renal cell carcinoma management. In mRCC, the rapid evolution from cytokine-based therapy to targeted therapy to immunotherapy with checkpoint blockade has revolutionized the field and drastically altered treatment outcomes. More recently, combination therapies have become a standard of care for most patients with mRCC. In this review, we highlight recent critical data that led to changes in treatment paradigms and provide a practical framework for the management of patients with mRCC. </jats:p>
収録刊行物
-
- JCO Oncology Practice
-
JCO Oncology Practice 18 (3), 187-196, 2022-03
American Society of Clinical Oncology (ASCO)